Aims And Background: We assessed the therapeutic results and tolerability of postoperative chemoradiotherapy with either oral UFT or 5-fluorouracil for carcinoma of the stomach.

Methods And Study Design: Forty-six patients treated with chemoradiotherapy following total or subtotal gastrectomy for gastric carcinoma formed the cohort evaluated. The group included 39 males and 7 females whose ages ranged from 21 to 74 years (median, 53 years). In all patients, surgical therapy was the initial approach with a curative intent. The types of operations performed were total gastrectomy in 11 or subtotal gastrectomy in 35 patients. Radiotherapy began from 14 to 161 days after surgery (median, 55 days). Twenty patients received concomitant oral UFT (200 mg/m2), and 26 patients were given 5-fluorouracil (425 mg/m2, iv bolus) concurrently with irradiation consisting of one or two cycles, usually as a 3-day bolus at the start and last 3 days of irradiation therapy for radiosensitizing purposes. The patients were treated using either cobalt-60 or 6 MV photons, and irradiation doses delivered to the tumor bed and regional lymphatics ranged from 40 to 50 Gy (median, 46 Gy).

Results: Median follow-up for the entire group was 24 months (range, 2-67). The 2-year overall survival of the entire group of patients was 64%. The 2-year overall survival rates for 5-fluorouracil and oral UFT groups were 72% and 66%, respectively (P = 0.3). Treatment-related factors were reviewed to identify any impact on survival. Analyses included type of surgery and dissection, fraction size, the total dose of irradiation and the type of chemotherapy. A significant detrimental effect in survival in the patients treated with D2 dissection compared to the patients treated with D1 dissection was noted (P = 0.01). Overall grade II-III toxicity of oral UFT was significantly lower than 5-FU (4 patients vs 14 patients, P = 0.03).

Conclusions: Concomitant use of oral UFT with radiation seems to be more tolerable and an equally effective regimen in the treatment of locally advanced gastric cancer compared with 5-fluorouracil. D2 dissection was found to have detrimental effects on survival in this cohort.

Download full-text PDF

Source
http://dx.doi.org/10.1177/030089160809400113DOI Listing

Publication Analysis

Top Keywords

oral uft
24
patients treated
16
patients
11
subtotal gastrectomy
8
concomitant oral
8
entire group
8
2-year survival
8
treated dissection
8
oral
6
uft
6

Similar Publications

Article Synopsis
  • The study examines the potential competition between adjuvant osimertinib and the current standard treatment, oral tegafur/uracil (UFT), for early-stage lung adenocarcinoma in Japan, particularly focusing on the impact of EGFR mutations on patient outcomes.
  • Researchers analyzed data from 1812 patients with stage I adenocarcinoma to compare 5-year disease-free survival (DFS) rates based on their EGFR mutation status and whether they received UFT treatment.
  • Results show that while the DFS rates varied by treatment and mutation status, adjuvant UFT did not provide a significant survival advantage, particularly in patients with EGFR mutations, indicating the need for alternative therapies in this group.
View Article and Find Full Text PDF
Article Synopsis
  • - The case report analyzes mucocutaneous leishmaniasis in HIV-positive and HIV-negative patients in Brazil, focusing on clinical presentation, diagnosis, treatment, and outcomes.
  • - It highlights the unique patterns of oral lesions in Brazil compared to other regions, where oral involvement is usually linked with more severe visceral leishmaniasis in immunocompromised patients.
  • - The findings stress the significance of understanding regional differences and the immune status of patients in the diagnosis and treatment of this neglected infectious disease.
View Article and Find Full Text PDF
Article Synopsis
  • The study explores the impact of adjuvant chemotherapy (UFT/LV) on disease-free survival (DFS) in high-risk stage II colon cancer patients compared to surgery alone, finding a significant DFS advantage with chemotherapy.
  • In a cohort of 1902 patients, those receiving UFT/LV for six months showed a higher 5-year DFS rate compared to those who had surgery only, but overall survival (OS) rates were similar between the two groups.
  • Key risk factors for poorer DFS and OS included male sex, older age (≥70 years), advanced cancer stage (T4), and lack of adjuvant chemotherapy, emphasizing the need for tailored treatment approaches in high-risk candidates.
View Article and Find Full Text PDF

Adjuvant Chemotherapy With UFT/LV UFT/LV Plus PSK in Stage II/III Colorectal Cancer.

Anticancer Res

February 2024

Division of Gastroenterological Surgery, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.

Background/aim: Uracil-tegafur+leucovorin (UFT/LV), an oral adjuvant therapy for stage II/III colorectal cancer, is non-inferior to standard weekly fluorouracil and folinate. Although polysaccharide K (PSK) has been evaluated as a postoperative adjuvant colorectal cancer drug, its efficacy remains unclear. This randomized phase II trial compared UFT/LV+PSK with UFT/LV as adjuvant chemotherapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!